Palantir Announces Hiring of First USG Chief Medical Officer
Palantir Technologies has appointed Dr. William J. Kassler, MD, MPH, as its first US Government Chief Medical Officer, enhancing its capabilities in the health sector. Dr. Kassler brings extensive experience from IBM Watson Health and the Centers for Medicare and Medicaid Services. Under his leadership, Palantir aims to continue its expansion in public and commercial health, building on its role during the Covid-19 pandemic. The company has recently strengthened its healthcare team, with a focus on addressing significant health challenges globally.
- Appointment of Dr. William J. Kassler enhances public health capabilities.
- Continued growth in the healthcare sector with expanded senior hires.
- Past success in mitigating the Covid-19 pandemic through technology.
- None.
Palantir Technologies today announced the hiring of Dr William J. Kassler, MD, MPH, as its first US Government Chief Medical Officer, bringing years of clinical and public health expertise to Palantir as it continues its expansion in the private and public health sectors.
Dr. Kassler is joining Palantir from IBM Watson Health and worked throughout his career at the intersection of clinical care and population health. He will lead the Public Health and Life Sciences teams across Palantir’s USG and international business.
Over the past few years, Palantir has grown its healthcare business and in recent months made significant new senior hires with deep domain expertise in life sciences, pharmaceuticals, and public health. Dr. Kassler and the expanded team will continue to build on Palantir’s success in public and commercial healthcare around the globe, putting its technology to work to solve the world’s most important health problems.
“Palantir has played a key role in mitigating the global Covid-19 pandemic, supporting more than 100 organizations in their response to the pandemic, and helping the U.S. and the U.K with vaccine distribution,” said Shyam Sankar, Palantir’s COO. “Palantir software has also been used in drug discovery, biotechnology, scientific research, and to mitigate disparities in public health. Dr. Kassler will play a key role in ensuring our healthcare work continues to prosper.”
“Palantir’s ability to lead so many international public health initiatives from the start of this pandemic was truly impressive and serves as a model for the type of technology investments governments around the world need to make,” said Dr. Kassler. “I’m inspired by Palantir’s mission and team, and excited to get to work. To emerge from this pandemic stronger, society will need to make significant improvements to how we approach public health.”
Dr. Kassler was IBM Watson Health’s Deputy Chief Health Officer and Chief Medical Officer for Government Health & Human Services and led their population health efforts. Before joining the private sector, he was Chief Medical Officer for the New England Region of the Centers for Medicare and Medicaid Services (CMS), and the State Health Officer for the New Hampshire Department of Health and Human Services. Dr. Kassler started his career at the Centers for Disease Control and Prevention (CDC).
He received his MD from the University of Massachusetts Medical School, an MS in nutrition from Case Western Reserve University, and an MPH from the University of California, Berkeley. He completed a primary care internal medicine residency at Brown University and was a Robert Wood Johnson Clinical Scholar at the University of California, San Francisco.
About Palantir Technologies
Palantir Technologies is a software company that builds enterprise data platforms for use by organizations with complex and sensitive data environments. From building safer cars and planes, to discovering new drugs and combating terrorism, Palantir helps customers across the public, private, and nonprofit sectors transform the way they use their data. Additional information is available at https://www.palantir.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir’s expectations regarding our healthcare business and the expected benefits of our software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include our ability to meet the unique needs of our customer; the failure of our platforms to satisfy our customer or perform as desired; the frequency or severity of any software and implementation errors; our platforms’ reliability; and our customer’s ability to modify or terminate contracts. Additional information regarding these and other risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005142/en/
FAQ
Who is the new Chief Medical Officer of Palantir Technologies?
What role will Dr. Kassler play at Palantir?
How has Palantir contributed to public health during the pandemic?
What is Palantir's focus in the healthcare sector?
What was Dr. Kassler's previous position before joining Palantir?
